{"id":4762,"date":"2025-10-10T15:17:22","date_gmt":"2025-10-10T12:17:22","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4762"},"modified":"2025-11-03T20:18:13","modified_gmt":"2025-11-03T17:18:13","slug":"wve-n531-exon-skipping-therapy-phase-2-clinical-trial-nct07209332","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/wve-n531-exon-skipping-therapy-phase-2-clinical-trial-nct07209332\/","title":{"rendered":"D\u00e9but de l&#039;essai clinique de phase 2 sur la th\u00e9rapie par saut d&#039;exon WVE-N531 pour la dystrophie musculaire de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Wave Life Sciences Ltd. a annonc\u00e9 sur son site Web ClinicalTrials.gov qu&#039;un essai clinique de phase 2 du WVE-N531 (th\u00e9rapie de saut d&#039;exon 53) d\u00e9butera en novembre 2025 avec 175 participants en Jordanie et au Royaume-Uni.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table des mati\u00e8res<\/h2><nav><ul><li><a href=\"#what-is-wve-n-531-exon-skipping-therapy\">Qu&#039;est-ce que la th\u00e9rapie par saut d&#039;exon WVE-N531<\/a><\/li><li><a href=\"#wve-n-531-exon-skipping-therapy-phase-2-nct-07209332\">Phase 2 du traitement par saut d&#039;exon WVE-N531 \u2013 NCT07209332<\/a><\/li><li><a href=\"#how-to-participate-in-the-wve-n-531-clinical-trial\">Comment participer \u00e0 l&#039;essai clinique WVE-N531<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-wve-n-531-exon-skipping-therapy\">Qu&#039;est-ce que la th\u00e9rapie par saut d&#039;exon WVE-N531<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>WVE-N531 est une th\u00e9rapie exp\u00e9rimentale de saut d&#039;exon en cours de d\u00e9veloppement comme th\u00e9rapie potentielle pour les patients atteints de DMD susceptibles de sauter l&#039;exon 53.<\/strong> Le WVE-N531 a \u00e9t\u00e9 con\u00e7u gr\u00e2ce aux modifications chimiques des oligonucl\u00e9otides les plus performantes de Wave, notamment la structure du squelette PN. Il a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin et de maladie p\u00e9diatrique rare de la Food and Drug Administration (FDA) des \u00c9tats-Unis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/fr\/mutations-and-deletions-amenable-to-exon-53-skipping-therapies-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Mutations et d\u00e9l\u00e9tions sensibles aux th\u00e9rapies par saut d&#039;exon 53 pour la dystrophie musculaire de Duchenne<\/a><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"847\" height=\"1024\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-847x1024.jpg\" alt=\"Mutations et d\u00e9l\u00e9tions sensibles aux th\u00e9rapies par saut d&#039;exon 53 pour la dystrophie musculaire de Duchenne\" class=\"wp-image-4566\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-847x1024.jpg 847w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-248x300.jpg 248w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-768x929.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1270x1536.jpg 1270w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1693x2048.jpg 1693w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-10x12.jpg 10w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-347x420.jpg 347w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-150x181.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-300x363.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-696x842.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1068x1292.jpg 1068w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1920x2323.jpg 1920w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping.jpg 1984w\" sizes=\"auto, (max-width: 847px) 100vw, 847px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"wve-n-531-exon-skipping-therapy-phase-2-nct-07209332\">Phase 2 du traitement par saut d&#039;exon WVE-N531 \u2013 NCT07209332<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Il s&#039;agit d&#039;une \u00e9tude d&#039;extension ouverte de phase 2 (OLE) visant \u00e0 \u00e9valuer l&#039;innocuit\u00e9, la tol\u00e9rance, l&#039;efficacit\u00e9, la pharmacocin\u00e9tique et la pharmacodynamique (PD) \u00e0 long terme par le biais de biomarqueurs exploratoires potentiels du WVE-N531 intraveineux (IV) chez les patients atteints de DMD qui ont particip\u00e9 \u00e0 une autre \u00e9tude sur le WVE-N531.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>D\u00e9but de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2025-11<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement du primaire (estim\u00e9)<\/strong>: 2029-03<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2029-03<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre de participants (estim\u00e9)<\/strong>: 175<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Type d&#039;\u00e9tude<\/strong>: Interventionnel<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Emplacement<\/strong>: Jordanie, Royaume-Uni<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c2ges admissibles aux \u00e9tudes<\/strong>: Enfant, Adulte, Personne \u00e2g\u00e9e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principaux crit\u00e8res d\u2019inclusion et d\u2019exclusion. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07209332\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07209332<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-to-participate-in-the-wve-n-531-clinical-trial\">Comment participer \u00e0 l&#039;essai clinique WVE-N531<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pour participer \u00e0 l&#039;essai clinique de phase 2 sur la th\u00e9rapie par saut d&#039;exon WVE-N531, vous pouvez utiliser les coordonn\u00e9es ci-dessous. <strong>Apprendre encore plus<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/fr\/how-to-participate-in-clinical-trials-for-duchenne\/\" target=\"_blank\" rel=\"noreferrer noopener\">Comment participer aux essais cliniques pour la maladie de Duchenne (DMD) ?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nom<\/strong>:Op\u00e9rations cliniques<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Num\u00e9ro de t\u00e9l\u00e9phone<\/strong>: 855-215-4687<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-mail<\/strong>: clinicaltrials@wavelifesci.com<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Wave Life Sciences Ltd. announced on its ClinicalTrials.gov website that a phase 2 clinical trial of WVE-N531 (Exon 53 Skipping Therapy) will begin in November 2025 with 175 participants in Jordan and the United Kingdom. What is WVE-N531 Exon Skipping Therapy WVE-N531 is an investigational exon skipping therapy being developed as a potential therapy for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4769,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,155,154,328,422,153,327],"class_list":["post-4762","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-exon-53","tag-exon-53-skipping","tag-exon-53-skipping-therapy","tag-exon-53-treatment","tag-wave-life-sciences","tag-wve-n531"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4762"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4762\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4769"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}